{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282679457281152.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.2325/jbcs.954"}},{"identifier":{"@type":"URI","@value":"http://www.springerlink.com/index/pdf/10.2325/jbcs.954"}},{"identifier":{"@type":"PMID","@value":"17485907"}},{"identifier":{"@type":"NAID","@value":"130004467483"}},{"identifier":{"@type":"NAID","@value":"10019480868"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2008047538"}}],"dc:title":[{"@language":"en","@value":"Current Clinical Trials of Endocrine Therapy for Breast Cancer"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"Breast cancer is a hormone-dependent cancer like prostate cancer and endometrial cancer. Estrogen plays important roles in the development and progression of breast cancer. Endocrine therapy is the treatment of choice for estrogen receptor- and/or progesterone receptor-positive breast cancer. Endocrine therapy has been used for several purposes, including chemoprevention, preoperative treatment, postoperative adjuvant treatment and treatment for recurrent diseases. A large number of clinical trials have provided evidence showing the clinical benefits of various endocrine therapies for the treatment of breast cancer. The current status and recent advances in endocrine therapy for breast cancer are reviewed based on the results of current clinical trials. Future perspectives of endocrine therapy are also discussed."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1420282801193609344","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"10248255"},{"@type":"NRID","@value":"1000010248255"},{"@type":"NRID","@value":"9000241668427"},{"@type":"NRID","@value":"9000011162823"},{"@type":"NRID","@value":"9000410185234"},{"@type":"NRID","@value":"9000252856960"},{"@type":"NRID","@value":"9000345441755"},{"@type":"NRID","@value":"9000410185885"},{"@type":"NRID","@value":"9000001970630"},{"@type":"NRID","@value":"9000410185862"},{"@type":"NRID","@value":"9000253369402"},{"@type":"NRID","@value":"9000410185910"},{"@type":"NRID","@value":"9000238287249"},{"@type":"NRID","@value":"9000383208460"},{"@type":"NRID","@value":"9000257910560"},{"@type":"NRID","@value":"9000253337499"},{"@type":"NRID","@value":"9000253661930"},{"@type":"NRID","@value":"9000253363693"},{"@type":"NRID","@value":"9000021835583"},{"@type":"NRID","@value":"9000253661951"},{"@type":"NRID","@value":"9000253373108"},{"@type":"NRID","@value":"9000253384620"},{"@type":"NRID","@value":"9000016763239"},{"@type":"NRID","@value":"9000018241852"},{"@type":"NRID","@value":"9000253344375"},{"@type":"NRID","@value":"9000253378286"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/read0035619"}],"foaf:name":[{"@language":"en","@value":"Kurebayashi Junichi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Breast and Thyroid Surgery, Kawasaki Medical School."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13406868"},{"@type":"EISSN","@value":"18804233"},{"@type":"NCID","@value":"AA1103354X"}],"prism:publicationName":[{"@language":"en","@value":"Breast Cancer"},{"@language":"en","@value":"Breast Cancer"}],"dc:publisher":[{"@language":"en","@value":"The Japanese Breast Cancer Society"},{"@language":"ja","@value":"日本乳癌学会"}],"prism:publicationDate":"2007","prism:volume":"14","prism:number":"2","prism:startingPage":"200","prism:endingPage":"214"},"reviewed":"false","url":[{"@id":"http://www.springerlink.com/index/pdf/10.2325/jbcs.954"},{"@id":"https://search.jamas.or.jp/link/ui/2008047538"}],"availableAt":"2007","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Clinical%20trial","dc:title":"Clinical trial"},{"@id":"https://cir.nii.ac.jp/all?q=Endocrine%20therapy","dc:title":"Endocrine therapy"},{"@id":"https://cir.nii.ac.jp/all?q=Chemo-endocrine%20therapy","dc:title":"Chemo-endocrine therapy"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011143857312256","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011144529305728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer: A prospective randomized study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011145380528384","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619412382720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group."}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619794384384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia."}]},{"@id":"https://cir.nii.ac.jp/crid/1360292620335554944","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621197538944","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"HER-2/neu Status Is a Determinant of Mammary Aromatase Activity <i>In vivo</i>: Evidence for a Cyclooxygenase-2-Dependent Mechanism"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574093584672640","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Overview of the main outcomes in breast-cancer prevention trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095287241216","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Resistance to endocrine therapy in breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095693423616","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"100 years of the endocrine battle against breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569516467072","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine Resistance"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855570498480512","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861295376103936","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Dual ErbB1/ErbB2 Inhibitor, Lapatinib (GW572016), Cooperates with Tamoxifen to Inhibit Both Cell Proliferation- and Estrogen-Dependent Gene Expression in Antiestrogen-Resistant Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861295376335360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combinations of Endocrine and Biological Agents: Present Status of Therapeutic and Presurgical Investigations"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043445647744","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044906714240","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519161057152","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418520454392704","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Adjuvant Endocrine Therapy for Premenopausal Women With Early Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699993770212736","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994032197504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994557228544","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994771880704","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group."}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995453993216","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996282453632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1– and/or ErbB-2–Positive, Estrogen Receptor–Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996327344128","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981468470101888","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Epirubicin–cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially: randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469046015488","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Combined Treatment With Buserelin and Tamoxifen in Premenopausal Metastatic Breast Cancer: a Randomized Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981469856180096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Exemestane Is Superior to Megestrol Acetate After Tamoxifen Failure in Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Randomized Double-Blind Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470333315968","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Activation Function-1 Domain of Estrogen Receptor Regulates the Agonistic and Antagonistic Actions of Tamoxifen"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470532566400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943650461056","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944160362496","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Postoperative Adjuvant Therapy With Tamoxifen, Tegafur Plus Uracil, or Both in Women With Node-Negative Breast Cancer: A Pooled Analysis of Six Randomized Controlled Trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262945583953536","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418790454400","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419573617152","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Treatment of Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544419912932736","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil as Adjuvant Therapy in Premenopausal Patients With Node-Positive Breast Cancer: The Zoladex Early Breast Cancer Research Association Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420315249408","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544420355947904","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Aromatase Inhibitors for Breast Cancer Prevention"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825893912079104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895013804416","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group."}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895191800064","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895536297344","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women: A report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA.1"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107368304609792","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Switching to Anastrozole Versus Continued Tamoxifen Treatment of Early Breast Cancer: Preliminary Results of the Italian Tamoxifen Anastrozole Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107369147092224","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes<SUBTITLE>The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial</SUBTITLE>"}]},{"@id":"https://cir.nii.ac.jp/crid/1363107371219338880","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843593911424","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate."}]},{"@id":"https://cir.nii.ac.jp/crid/1363388843931368704","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@value":"Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845060406272","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Mechanisms of Tamoxifen Resistance: Increased Estrogen Receptor-HER2/neu Cross-Talk in ER/HER2-Positive Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845093456384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"ATAC trial update"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846108606208","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320197488768","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794000594176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Additive antitumor effect of concurrent treatment of 4-hydroxy tamoxifen with 5-fluorouracil but not with doxorubicin in estrogen receptor-positive breast cancer cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795526344832","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268994475136","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Retrospective Analysis of Time to Recurrence in the ATAC Trial According to Hormone Receptor Status: An Hypothesis-Generating Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269372256384","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269696643328","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233270106787968","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Neoadjuvant Treatment of Postmenopausal Breast Cancer With Anastrozole, Tamoxifen, or Both in Combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined With Tamoxifen (IMPACT) Multicenter Double-Blind Randomized Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271002677248","@type":"Article","relationType":["references","cites"],"jpcoar:relatedTitle":[{"@value":"Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233271265993600","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Cyclophosphamide, Methotrexate, and Fluorouracil Versus Tamoxifen Plus Ovarian Suppression as Adjuvant Treatment of Estrogen Receptor–Positive Pre-/Perimenopausal Breast Cancer Patients: Results of the Italian Breast Cancer Adjuvant Study Group 02 Randomized Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1570009750541149312","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Chemotherapy versus combination of chemotherapy and endocrine therapy in advanced breast cancer. A prospective randomized study"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225517615360","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Cyclophosphamide, methotrexate, and fluorouracil versus tamoxifen plus ovarian suppression as adjuvant treatment of estrogen receptor-positive pre-/per-imenopausal breast cancer patients : results of the Italian Breast Cancer Adjuvant Study Group 02 randomized trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225517858816","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225517859968","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Goserelin, a depot gonadotrophin-releasing hormone agonist in the treatment of premenopausal patients with metastatic breast cancer. German Zoladex Trial Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1570291225517861120","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer : results of a phase III randomized double-blind trial. The Exemestane Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572700494569088","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Letrozole, a new oral aromatase inhibitor for advanced breast cancer : double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854175471037696","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"First mature analysis of the Intergroup Exemestane Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1570854175471279744","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650447745152","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer : a meta-analysis of the ARNO 95 Trila, ABCSG Trial 8, and the ITA Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650447992576","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women : results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135650447994880","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1571417125424702208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Postoperative adjuvant therapy for premenopausal patients with breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1571417125424705792","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698599990987904","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698600401166976","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1571698600401410944","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro"}]},{"@id":"https://cir.nii.ac.jp/crid/1571980075377878016","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival : an overview of the randomised trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1572261551577366144","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish trial."}]},{"@id":"https://cir.nii.ac.jp/crid/1572543025331300480","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Preoperative treatment of postmenopausal breast cancer patients with letrozole : A randomized double-blind multicenter study"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543025331541888","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Combinations of endocrine and biological agents : present status of therapeutic and presurgical investigations"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543025331543040","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent : initial results from intergroup trial 0100 (SWOG-8814)"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543025331545344","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women : results of a North American multicenter randomized trial. Arimidex Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1572543025331547776","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A randomized crossover trial of tamoxifen versus ovarian ablation for metastatic breast cancer in premenopausal women : a report of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial MA. 1"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500308010112","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"ABCSG and the GABG : Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen : combined results of ABCSG trial 8 and ARNO 95 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500308011264","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients : preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate)"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500308255616","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women : a prospective combined analysis of two multicenter trials"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387450261676928","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Epirubicin-cyclophosphamide adjuvant chemotherapy plus tamoxifen administered concurrently versus sequentially : randomized phase III trial in postmenopausal node-positive breast cancer patients. A GEICAM 9401 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1573387450720221312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"乳癌内分泌療法の最近の話題 : 2007年 St. Gallen 国際会議より"},{"@language":"en","@value":"Current topics on endocrine therapy of breast cancer discussed at the 10th St. Gallen International Conference in 2007"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400214853248","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Activation function-1 domain of estrogen receptor regulates the agonistic and antagonistic actions of tamoxifen"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400215097216","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1573950400215101568","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer : results of overview analysis of two phase III trials. Arimidex Study Group"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231875191560832","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen?"}]},{"@id":"https://cir.nii.ac.jp/crid/1574231875191564416","@type":"Article","relationType":["cites"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer : evidence from a phase III randomized trial"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0029301028"},{"@type":"CROSSREF","@value":"10.2325/jbcs.954"},{"@type":"CIA","@value":"10019480868"},{"@type":"CIA","@value":"130004467483"},{"@type":"OPENAIRE","@value":"doi_dedup___::2d3dba27e9fa0f1203989c76516166a3"}]}